HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Optimum therapeutic approaches for lupus nephritis: what therapy and for whom?

Abstract
The optimum therapy for patients with lupus nephritis is a hotly debated topic. Prospective randomized studies in patients with proliferative lupus nephritis have established the superiority of cyclophosphamide to azathioprine, both of which are used in combination with corticosteroids. Although high-dose, intermittent administration of cyclophosphamide (pulse therapy) has significantly reduced the toxicity associated with this drug, premature ovarian failure and infections remain considerable problems. Short-term to intermediate-term, randomized controlled trials have shown that mycophenolate mofetil is a good option for the induction and maintenance of remission in lupus nephritis patients. Additional longer-term trials involving more patients and stricter outcomes based on renal function are needed, however, before claims that mycophenolate mofetil is superior to cyclophosphamide can be substantiated. Until such data are available, physicians caring for patients with lupus nephritis can use mycophenolate mofetil as induction or maintenance therapy for selected patients under close observation. Small noncontrolled trials with short-term follow-up suggest that up to 50% of patients who are refractory to cyclophosphamide might have a clinically significant response to rituximab, a monoclonal antibody directed against B cells.
AuthorsDimitrios T Boumpas, Prodromos Sidiropoulos, George Bertsias
JournalNature clinical practice. Rheumatology (Nat Clin Pract Rheumatol) Vol. 1 Issue 1 Pg. 22-30 (Nov 2005) ISSN: 1745-8382 [Print] United States
PMID16932624 (Publication Type: Journal Article, Review)
Chemical References
  • Glucocorticoids
  • Immunosuppressive Agents
Topics
  • Drug Therapy, Combination
  • Glucocorticoids (therapeutic use)
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Lupus Nephritis (drug therapy)
  • Randomized Controlled Trials as Topic (standards)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: